作者回复：重新定义复发/难治性多发性骨髓瘤治疗的价值。
The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.
机构信息
1 The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle.
2 Institute for Clinical and Economic Review Boston, Massachusetts.
出版信息
J Manag Care Spec Pharm. 2018 Jul;24(7):712-713. doi: 10.18553/jmcp.2018.24.7.712.
Funding for the Carlson et al. study was provided in part by the Institute for Clinical and Economic Review. Ollendorf, Synnott, Chapman, and Pearson disclosed grants from Blue Shield of California Foundation, California Health Care Foundation, Laura and John Arnold Foundation, Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, OmedaRx, United Healthcare, Kaiser Permanente, Premera, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Takeda, Pfizer, Novartis, Lilly, Spark Therapeutics, Sanofi, Prime Therapeutics, and Health Care Service Corporation. Carlson disclosed grants from the Institute for Clinical and Economic Review and personal fees from Seattle Genetics, Genentech, and Pfizer. Russo, Guzauskas, Liu, and Brouwer have nothing to disclose.
卡尔森等人的研究部分由临床与经济评价研究所提供资金支持。奥伦多夫、辛诺特、查普曼和皮尔逊披露了来自加州蓝盾基金会、加州医疗保健基金会、劳拉和约翰·阿诺德基金会、安泰、AHIP、Anthem、加州蓝盾、CVS 健康、Express Scripts、哈佛朝圣者健康保健、OmedaRx、联合健康、Kaiser Permanente、Premera、阿斯利康、基因泰克、葛兰素史克、强生、默克、国家药品理事会、武田、辉瑞、诺华、礼来、Spark Therapeutics、赛诺菲、Prime Therapeutics 和医疗保健服务公司的资助。卡尔森披露了来自临床与经济评价研究所的资助以及来自西雅图遗传学公司、基因泰克和辉瑞的个人酬金。鲁索、古扎乌斯卡斯、刘和布鲁尔没有需要披露的信息。
Zotero 插件